Lightray OLE

The LIGHTRAY trial enrolled adults with pulmonary arterial hypertension (PAH). PAH is a type of high blood pressure that affects the arteries that go from the heart to the lungs. It can cause strain on the right side of the heart. This LIGHTRAY EXTENSION trial is being conducted to test the long-term safety of sotatercept given using a weight-banded dosing method. The weight-banded dosing (dose based on weight bands with a different dose assigned to each band) of sotatercept is not currently approved by the Australian TGA outside of clinical trials. However, weight-based dosing (dose based on exact body weight) has been approved in some countries, including Australia, for treating PAH in adults. This trial is for participants who completed the treatment phase of the LIGHTRAY trial (including Visit 11) and did not discontinue sotatercept.